Skye Bioscience, INC

Skye Bioscience and Redx Pharma announce a definitive agreement to merge, creating Fibrx Therapeutics, a fibrosis-focused company, backed by approximately $125 million in combined financings.

Skye Bioscience shareholders approved an amendment to increase authorized common stock from 100 million to 300 million shares.

Skye Bioscience faces potential delisting risk after falling below Nasdaq's $10 million minimum stockholders' equity requirement.

Skye Bioscience files an amendment to a previous 8-K report to correct a clerical error regarding the total number of shares underlying repriced stock options.

Skye Bioscience repriced all outstanding employee stock options to $0.6150 and appointed John P. Sharp as Chief Financial Officer.

Skye Bioscience, Inc. received a deficiency letter from Nasdaq for failing to maintain the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Skye Bioscience terminates nimacimab R&D, pauses clinical trials, and focuses on a proposed acquisition of Redx Pharma, while facing ongoing financial and listing challenges.

Skye Bioscience reports Q1 2026 financial results, detailing progress and challenges in nimacimab development, alongside Nasdaq listing concerns and ongoing litigation.

Skye Bioscience's Q3 report reveals mixed Phase 2a results for nimacimab, with monotherapy failing its primary endpoint but combination with semaglutide showing significant weight loss and improved outcomes.

Skye Bioscience reported a significant increase in net loss for Q2 2025 driven by higher research and development expenses for its lead obesity drug candidate, nimacimab, while maintaining sufficient cash for the next 12 months.

Skye Bioscience continues to advance its clinical program for nimacimab, a CB1 receptor-targeting antibody, while reporting a net loss of $11.1 million for the first quarter of 2025.

Skye Bioscience reported its Q3 2024 financial results, highlighted by a significant increase in cash reserves and the advancement of its Phase 2 clinical trial for nimacimab, its obesity treatment candidate.

Skye Bioscience details its financial performance for 2024 and provides updates on its clinical development programs, particularly focusing on nimacimab for obesity treatment.

Skye Bioscience details its capital structure, stock rights, and ongoing clinical programs for nimacimab and SBI-100 Ophthalmic Emulsion in its latest 10-K filing.

Punit Dhillon, Chief Executive Officer and a Director of Skye Bioscience, Inc., received 1,090,000 shares of common stock on August 7, 2026.

Director Karen L. Smith acquired 75,000 stock options in Skye Bioscience, Inc. on March 31, 2026.

Skye Bioscience's Chief Scientific Officer, Christopher Twitty, has repriced several stock options, adjusting exercise prices and vesting schedules.

Annalisa Jenkins, a Director at Skye Bioscience, Inc., acquired stock options representing 75,000 shares.

Skye Bioscience Director Deborah H. Charych acquired 75,000 stock options with an exercise price of $0.615.

Paul A. Grayson, a Director at Skye Bioscience, Inc., acquired 75,000 stock options with an exercise price of $0.615.

Skye Bioscience is seeking stockholder approval to triple its authorized common stock to 300 million shares and ratify its board and auditors.

Skye Bioscience, Inc. announces its 2025 Annual Meeting of Stockholders to be held on June 6, 2025, outlining key proposals for voting, including the election of directors and ratification of the company's independent auditor.

Skye Bioscience is seeking stockholder approval on key governance matters, including the election of directors, ratification of the auditor, and executive compensation, as it advances its CB1-targeted obesity therapeutic program.

Skye Bioscience is asking stockholders to approve an amended equity incentive plan to increase the number of shares available for issuance and extend the plan's expiration date.

Skye Bioscience files an amendment to its S-1 registration statement to correct a scrivener's error in the auditor's report regarding the date of the original report.

Skye Bioscience registers for the potential resale of up to 33.7 million shares of common stock by selling securityholders following a merger and several private placements.

5AM Partners II, a significant shareholder in Skye Bioscience, Inc., has adopted a new 10b5-1 plan to sell up to 1.51 million shares of common stock between January and November 2026.

Schonfeld Strategic Advisors LLC has filed an amended Schedule 13G, reporting beneficial ownership of 3.60% of Skye Bioscience, Inc.'s common stock.

Schonfeld Strategic Advisors LLC has reported a 5.22% beneficial ownership stake in Skye Bioscience, Inc., holding 1,617,697 shares of common stock.

Sphera Funds Management Ltd. and its affiliates have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.77% in Skye Bioscience, Inc.'s common stock as of March 31, 2025.